In recent years, inhibitors of poly(ADP-ribose) polymerase (PARP) have emerged as a promising new therapeutic approach for ovarian cancer treatment, especially for high-grade ovarian carcinoma with mutations in the BRCA1 or BRCA2 tumor suppressor genes (1). This evidence concerns the gene PARP1 and ovarian carcinoma.